Moderna, Inc. (MRNA): Total Assets
$12.34B
As of 2025-12-31
$10.96B
As of 2026-06-30
-21.9%
3-year compound annual growth
+11.0%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $12.34B | -12.8% | 2026-02-20, Balance as of period end |
| 2024-12-31 | $14.14B | -23.2% | 2026-02-20, Balance as of period end |
| 2023-12-31 | $18.43B | -28.7% | 2025-02-21, Balance as of period end |
| 2022-12-31 | $25.86B | +4.8% | 2024-02-23, Balance as of period end |
| 2021-12-31 | $24.67B | +236.2% | 2023-02-24, Balance as of period end |
| 2020-12-31 | $7.34B | +361.6% | 2022-02-25, Balance as of period end |
| 2019-12-31 | $1.59B | -19.0% | 2021-02-26, Balance as of period end |
| 2018-12-31 | $1.96B | +80.9% | 2020-02-27, Balance as of period end |
| 2017-12-31 | $1.08B | n/a | 2019-03-13, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Moderna, Inc. (MRNA) | 2025-12-31 | $12.34B | -12.8% |
| Qiagen N.V. (QGEN) | 2025-12-31 | $6.28B | +10.4% |
| Exelixis, Inc. (EXEL) | 2026-01-02 | $2.84B | -3.5% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $2.53B | +22.4% |
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $4.63B | +24.5% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $2.59B | +1.1% |
| Novavax Inc (NVAX) | 2025-12-31 | $1.18B | -24.6% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $514.16M | +4.8% |
| Repligen Corp (RGEN) | 2025-12-31 | $2.95B | +4.2% |
Compare MRNA, QGEN, EXEL, HALO side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗